A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

To join this study, you need to be at least 18 years old and have a confirmed diagnosis of prostate cancer that has spread. Your cancer also needs to be resistant to hormone therapy, meaning it's still growing despite hormone treatments. We'll check this by looking at your scans and blood tests to make sure there's evidence your cancer is progressing.

You must have had your testosterone levels lowered, either through surgery or ongoing hormone therapy, and your testosterone levels need to be very low. You also need to have tried one, but only one, specific hormone therapy drug in the past (like enzalutamide, apalutamide, or darolutamide) and your cancer must have progressed while on it. Your health in general should be good enough to participate in a clinical trial. If you are a candidate for cabazitaxel as a treatment option, you should not have received more than 6 cycles of docetaxel before for your cancer when it was hormone-sensitive.

If you decide to join this study, you would first go through a screening process to make sure you're a good fit. This might involve blood tests, scans (like CT, MRI, or bone scans), and a review of your medical history. Once enrolled, you would receive either the new drug combination (Xaluritamig plus Abiraterone) or one of the standard treatments. The specific details of how often you would take the medication and attend appointments would be explained by the study team, but generally, there will be regular visits for check-ups, blood tests, and scans to monitor your health and how the treatment is working. The total length of your participation would depend on how your treatment is progressing and what the study protocol dictates, including follow-up after your treatment.